By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aragen Bioscience has licensed the rights to use Cevec Pharmaceuticals' CAP-T protein production technology in its custom recombinant cell line offerings, CEVEC said today.

The license gives Aragen the rights to offer its research clients custom recombinant human cell lines that express biotherapeutic proteins and antibodies using the Cevec technology, which is based on CAP cells, a cell line used for stable protein production.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.